ArticleJournal of Cancer2020
LRG1 Suppresses Migration and Invasion of Esophageal Squamous Cell Carcinoma by Modulating Epithelial to Mesenchymal Transition.
Article in Journal of Cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Review
- Article
- LRG1 in cancer: mechanisms, potential therapeutic target, and use in clinical diagnosis.Molecular biology reports · 2025Review
- LRG1 and SDR16C5 protein expressions differ according to HPV status in oropharyngeal squamous cell carcinoma.Scientific reports · 2024Article
- [LRG1 inhibits hepatic macrophage activation by enhancing TGF-β1 signaling to alleviate MAFLD in mice].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023Article
- LRG-1 promotes fat graft survival through the RAB31-mediated inhibition of hypoxia-induced apoptosis.Journal of cellular and molecular medicine · 2022Article
- LRG1 mediated by ATF3 promotes growth and angiogenesis of gastric cancer by regulating the SRC/STAT3/VEGFA pathway.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2022Article
- Leucine rich alpha-2-glycoprotein 1 (Lrg1) silencing protects against sepsis-mediated brain injury by inhibiting transforming growth factor beta1 (TGFβ1)/SMAD signaling pathway.Bioengineered · 2022Article
- The role of leucine-rich alpha-2-glycoprotein-1 in proliferation, migration, and invasion of tumors.Journal of cancer research and clinical oncology · 2022Review
- LRG1: an emerging player in disease pathogenesis.Journal of biomedical science · 2022Review
- Colorectal cancer-associated fibroblasts promote metastasis by up-regulating LRG1 through stromal IL-6/STAT3 signaling.Cell death & disease · 2021Article
- LRG1 Promotes Metastatic Dissemination of Melanoma through Regulating EGFR/STAT3 Signalling.Cancers · 2021Article
- Paradoxical Roles of Leucine-Rich αFrontiers in cell and developmental biology · 2021Article
- Research Progress on Leucine-Rich Alpha-2 Glycoprotein 1: A Review.Frontiers in pharmacology · 2021Review
- Global Histone H3 Lysine 4 Trimethylation (H3K4me3) Landscape Changes in Response to TGFβ.Epigenetics insights · 2021Article
- LRG1 promotes epithelial-mesenchymal transition of retinal pigment epithelium cells by activating NOX4.International journal of ophthalmology · 2021Article
- SUMOylation of HSP27 regulates PKM2 to promote esophageal squamous cell carcinoma progression.Oncology reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.